Abstract
Cancer therapy has witnessed major advances in the last few decades. However, the conventional therapies have a narrow therapeutic application, and the responses produced are generally unpredictable and are often non-curative. New strategies to combat cancer are being developed, one of the most promising of which is the use of non-genotoxic chemicals that are able to rescue the tumor suppressor function of p53 in cancer cells. In this review, we first discuss: (i) the current knowledge on the role of p53 in determining the fate of human normal and malignant cells following exposure to cancer therapeutic agents; and (ii) the biological consequences of the failure of cancer cells to implement p53-mediated responses in terms of development of highly metastatic “karyoplasts” which exhibit both selfrenewal and treatment-resistant properties. We next provide an update on the potential anticancer properties of diverse types of pharmacological modulators of p53, including histone deacetylase inhibitors (e.g., trichostatin A), aromatase inhibitors (e.g., Anastrozole), and the nuclear export inhibitor leptomycin B. In addition, we highlight the various shortcomings of in vitro assays that are universally used for preclinical evaluation of anti-neoplastic properties of new drugs, and describe alternative cytotoxicity assays that circumvent some of these shortcomings.
Keywords: p53 signaling, pharmacological modulators of p53, cancer therapy, cytotoxicity assays, apoptosis, accelerated senescence
Current Signal Transduction Therapy
Title: Pharmacological Modulation of p53 Function in Cancer Therapy
Volume: 3 Issue: 3
Author(s): Razmik Mirzayans and David Murray
Affiliation:
Keywords: p53 signaling, pharmacological modulators of p53, cancer therapy, cytotoxicity assays, apoptosis, accelerated senescence
Abstract: Cancer therapy has witnessed major advances in the last few decades. However, the conventional therapies have a narrow therapeutic application, and the responses produced are generally unpredictable and are often non-curative. New strategies to combat cancer are being developed, one of the most promising of which is the use of non-genotoxic chemicals that are able to rescue the tumor suppressor function of p53 in cancer cells. In this review, we first discuss: (i) the current knowledge on the role of p53 in determining the fate of human normal and malignant cells following exposure to cancer therapeutic agents; and (ii) the biological consequences of the failure of cancer cells to implement p53-mediated responses in terms of development of highly metastatic “karyoplasts” which exhibit both selfrenewal and treatment-resistant properties. We next provide an update on the potential anticancer properties of diverse types of pharmacological modulators of p53, including histone deacetylase inhibitors (e.g., trichostatin A), aromatase inhibitors (e.g., Anastrozole), and the nuclear export inhibitor leptomycin B. In addition, we highlight the various shortcomings of in vitro assays that are universally used for preclinical evaluation of anti-neoplastic properties of new drugs, and describe alternative cytotoxicity assays that circumvent some of these shortcomings.
Export Options
About this article
Cite this article as:
Mirzayans Razmik and Murray David, Pharmacological Modulation of p53 Function in Cancer Therapy, Current Signal Transduction Therapy 2008; 3 (3) . https://dx.doi.org/10.2174/157436208785699721
DOI https://dx.doi.org/10.2174/157436208785699721 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Application of Chitosan in Dental Specialities
Mini-Reviews in Medicinal Chemistry Parathyroid Hormone Determination in Ultrasound-Guided Fine Needle Aspirates Allows the Differentiation between Thyroid and Parathyroid Lesions: Our Experience and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets p53 Activation by Blocking Snail : A Novel Pharmacological Strategy for Cancer
Current Pharmaceutical Design Editorial (Thematic Issue: Nanosystems: An Innovative Tools for Medicinal Chemistry)
Current Topics in Medicinal Chemistry The Antimitotic Potential of PARP Inhibitors, An Unexplored Therapeutic Alternative
Current Topics in Medicinal Chemistry Novel Nanocolloidal Carriers for Noninvasive Vaccine Delivery
Current Drug Therapy Low Dose of Anisodine Hydrobromide Induced Neuroprotective Effects in Chronic Cerebral Hypoperfusion Rats
CNS & Neurological Disorders - Drug Targets Immunotherapy with Dendritic Cells as a Cancer Treatment: Perspectives and Therapeutic Potential
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Immune Checkpoint Inhibitors in the Treatment of Cancer
Current Reviews in Clinical and Experimental Pharmacology Targeting the HIF-1α/Cav-1 Pathway with a Chicory Extract/Daidzein Combination Plays a Potential Role in Retarding Hepatocellular Carcinoma
Current Cancer Drug Targets Metabolism of Flavonoids in Human: A Comprehensive Review
Current Drug Metabolism Plasmid DNA Gene Therapy by Electroporation: Principles and Recent Advances
Current Gene Therapy GPR55 and its Interaction with Membrane Lipids: Comparison with Other Endocannabinoid-Binding Receptors
Current Medicinal Chemistry Arginyl Aminopeptidase-Like 1 (RNPEPL1) Is an Alternatively Processed Aminopeptidase with Specificity for Methionine, Glutamine, and Citrulline Residues
Protein & Peptide Letters Therapeutic Potential of Mucoadhesive Drug Delivery Systems - An Updated Patent Review
Recent Patents on Drug Delivery & Formulation Role of Protein Tyrosine Phosphatase in Regulation of Cell Signaling Cascades Affecting Tumor Cell Growth: A Future Perspective as Anti-Cancer Drug Target
Current Pharmaceutical Biotechnology Boron-Containing Compounds as Preventive and Chemotherapeutic Agents for Cancer
Anti-Cancer Agents in Medicinal Chemistry Human Papillomavirus Selected Properties and Related Cervical Cancer Prevention Issues
Current Pharmaceutical Design Exploiting HPV-Induced Carcinogenesis for a Rational Drug Development in Cervical Cancer
Current Cancer Drug Targets Current Status of Epigenetics and Anticancer Drug Discovery
Anti-Cancer Agents in Medicinal Chemistry